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Abstract
Porcine reproductive and respiratory syndrome (PRRS) is a disease of swine, caused by an arterivirus, the PRRS virus (PRRSV).
This virus infects pigs worldwide and causes huge economic losses. Due to genetic drift, current vaccines are losing their
power. Adaptable vaccines could provide a solution to this problem. This study aims at producing in planta a set of antigens
derived from the PRRSV glycoproteins (GPs) to be included in a subunit vaccine. We selected the GP3, GP4 and GP5 and
optimized these for production in an Arabidopsis seed platform by removing transmembrane domains (Tm) and/or adding
stabilizing protein domains, such as the green fluorescent protein (GFP) and immunoglobulin (IgG) ‘Fragment crystallizable’
(Fc) chains. Accumulation of the GPs with and without Tm was low, reaching no more than 0.10% of total soluble protein
(TSP) in homozygous seed. However, addition of stabilizing domains boosted accumulation up to a maximum of 2.74% of
TSP when GFP was used, and albeit less effectively, also the Fc chains of the porcine IgG3 and murine IgG2a increased
antigen accumulation, to 0.96% and 1.81% of TSP respectively, while the murine IgG3 Fc chain did not. Antigens with Tm
were less susceptible to these manipulations to increase yield. All antigens were produced in the endoplasmic reticulum
and accordingly, they carried high-mannose N-glycans. The immunogenicity of several of those antigens was assessed and
we show that vaccination with purified antigens did elicit the production of antibodies with virus neutralizing activity in
mice but not in pigs.
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Introduction
PRRSV is a pig pathogen that emerged in the late eighties in
North America and North Europe [1,2]. Since its emergence,
PRRSV has spread across the globe. It is considered one of the
major pathogens affecting pig industries and causes severe
economic losses worldwide [3,4]. It provokes respiratory distress
in pigs of all ages, but is especially problematic when infecting
pregnant sows, leading to late abortion, early farrowing and birth
of dead or weakened piglets [5]. Lately, more virulent strains with
a high incidence of pig mortality have been circulating [4,6].
PRRSV is an enveloped RNA virus belonging to the family of
the Arteriviridae. Two genotypes, a North American (NA-type) and
a European (EU-type), have been identified, which again can be
divided in several subtypes [7,8]. It has multiple open reading
frames embedded in its 15-kb long genome [9]. Open reading
frames 2 to 7 code for the glycoprotein (GP) 2, the E protein, GP3,
GP4, GP5, the M protein and the nucleocapsid protein N,
respectively [9–12]. Of these structural proteins, the GP5 and the
M protein are the major proteins found in the lipid envelope and
occur as a disulfide-linked heterodimer [13]. The minor envelope
proteins, i.e. GP2, GP3, GP4 and the E protein, are present as
non-covalently associated heteromultimers.
PRRSV infection induces a defective immune response with late
appearance of neutralizing antibodies and delayed cell mediated
immunity [14,15]. This allows the infection to be persistent and
makes it difficult to eliminate PRRSV from an infected herd.
Control of PRRSV is focused on the administration of prophy-
lactic vaccines to minimize the clinical impact of an infection. The
vaccines currently used in the field consist of killed and live,
attenuated vaccines. Commercial killed vaccines are safe and can
provide some protection against homologous viruses, but are
totally ineffective against heterologous strains [16,17]. The
available attenuated vaccines, however, are very effective against
homologous challenges and can, to a certain degree, even cross
protect against heterologous strains, but they raise safety concerns
because of their live viral content [16–20]. The attenuated vaccine
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can revert to virulence and cause infection in the vaccinated herd
instead of preventing it. This has been documented for PRRSV on
several occasions [19–21]. There is thus an urgent need for an
adaptable, safe and effective PRRSV vaccine, such as a rationally
engineered subunit vaccine. The latter is inherently safe because
no virus is present and by incorporating elements known to be
important in immunity against PRRSV, could be very effective.
To this goal, we selected GP3, GP4 and GP5 of the European
prototype PRRSV, the ‘Lelystad Virus’ (LV), to be included in a
subunit vaccine. Since viral glycoproteins are complex proteins
that cannot be correctly produced in bacteria, we opted to express
them in the seed of Arabidopis thaliana, a production platform that
has previously been used to generate several heterologous proteins
to levels as high as 15% of total soluble protein (TSP) [22–26].
Production of high-value pharmaceuticals in plants has gained
popularity during the last decades, due to intrinsic advantages
offered by this production platform, such as flexible scale up, the
absence of human or animal pathogens, and the potential for the
cheap production and storage of complex proteins [27–29]. The
technology has reached maturity and several plant made
pharmaceuticals are in clinical trials, on the road to the market
[30]. Different plant species and tissues have been employed for
the production of PRRSV vaccines. Banana leaves [31], potato
tubers [32] and tobacco leaves [33,34] were used to express the
GP5 and recombinant variants thereof. The M protein was
produced in corn calli [35] and the N protein in soybean seed [36].
Antigen accumulation was relatively low, ranging from 0.011% of
TSP for GP5 expressed in tobacco to 0.65% of TSP for the N
protein expressed in soybean seed and none of the antigens were
purified. However, to overcome economic hurdles during vaccine
production, it is essential that the antigens accumulate to high
levels and that an efficient purification protocol is in place. With
this in mind, we manipulated the GP3, GP4 and GP5 coding
sequence to augment their production and to facilitate purification
by removing transmembrane domains (Tm), adding affinity tags
and/or fusing them to stabilizing protein domains, such as the
‘Fragment crystallizable’ (Fc) chain of immunoglobulins (IgGs) or
the green fluorescent protein (GFP), hence giving rise to an entire
set of antigen formats derived from the EU-prototype LV. All
these different constructs were cloned in a seed-specific expression
cassette [37], transformed into Arabidopsis thaliana and the resulting
transformants screened for antigen content. The antigens were
characterized and evaluated for their ease of production and
purification. Further, the immunogenicity of the antigens and their
potential to raise neutralizing antibodies were investigated by
vaccinating mice, and subsequently piglets, with purified antigens.
This paper details the in planta production of a set of antigenic
proteins derived from the GPs of the EU-prototype LV. We show
that the antigens are correctly produced in the seed, accumulate to
levels that are economically feasible (1% of TSP or more; [38]) and
can be purified by single-step affinity chromatography. Addition-
ally, we assayed the immunogenicity of several antigens in both a
murine and porcine model.
Results
Antigen expression in A. thaliana seed
The PRRSV envelope proteins GP3, GP4 and GP5 (Figure 1B)
were selected and expressed as different formats in A. thaliana seed
(Figure 1C). Both full-length GP4 and GP5, as well as their
truncated formats without Tm (hereafter referred to as GP4-Tm
and GP5-Tm) were cloned into an expression cassette with
regulatory sequences of Phaseolus vulgaris designed for high seed-
specific expression [22,24,37] (Figure 1A). All antigens were
targeted to the endoplasmic reticulum (ER) by N-terminal fusion
to the signal peptide of a 2S seed storage protein, and retained
there via a C-terminal KDEL-tag. Little is known about the
transmembrane topology of the full-length GP4 and GP5. The C-
terminal hydrophobic domain of GP4 is predicted to span the
membrane once, whereas the central hydrophobic domain of GP5
is predicted to span the membrane anywhere from one to three
times [10,39]. In vivo, transit through the secretory pathway
decorates the GPs with complex mammalian N-glycans
[10,13,40]. However, retaining the GPs in the ER will cause
their N-glycans to be of the high-mannose type [39]. To evaluate
the influence of these ER-associated high-mannose glycans on
antigen immunogenicity, a deglycosylated format of the GP4-Tm
(named sGP4-Tm) was designed. This was done by mutating the
asparagine in the consensus sequence N-x-S/T (with x being any
amino acid except proline) into a glutamine for each of the four
N-glycan attachment sites that was present. For GP3, only a
truncated format without Tm (named GP3-Tm) was cloned.
Fusions were also made between these proteins and stable protein
domains, such as the GFP and the Fc chains of the porcine IgG3
(pFc), the murine IgG3 (mFc3), and the murine IgG2a (mFc2a),
generating a whole set of antigenic PRRSV proteins (Figure 1C).
All constructs except the murine Fc fusions, contain the His6-tag.
For every antigen construct, twenty transformants were generated,
and the line with the highest antigen content and in which the
T-DNA was integrated at a single locus, as determined by
segregation analysis (see Material & methods), was retained, selfed
and propagated to homozygosity.
Transformants could be obtained for all GP3 derived
constructs, except for GP3-Tm. Extracts from homozygous GP3-
Tm:pFc, GP3-Tm:mFc2a and GFP:GP3-Tm seed stocks were
analyzed by western blotting with the anti- (a-) GP3 monoclonal
antibody (mAb) VII2D that recognizes the linear epitope
MWCKIGHDRCEE [41]. This revealed several glycoforms
migrating at their expected theoretical molecular weight (Mw)
ranging from 46.3 kDa (one of the six or seven N-glycan
attachment sites occupied) to 60.3 kDa (fully glycosylated)
(Figure 2A; Table 1). Mainly for the GFP:GP3-Tm also some
non-reduced multimeric structures could be seen between 100 and
150 kDa, together with some degradation products around
37 kDa.
The GP4 seed stocks were analyzed with the a-GP4 mAb
XVI11C that recognizes the linear epitope GVSAAQEKISFG
[42] (Figure 2B). Since GP4 and GP4-Tm carry four N-glycan
attachment sites, four different glycoforms could be detected for
both, with those of GP4 migrating slower than those of GP4-Tm,
due to the presence of the Tm (Figure 2B). However, a differential
glycosylation preference was observed, since GP4 showed a higher
intensity of its upper band and a very weak signal of the second
lowest band, whereas GP4-Tm showed a higher intensity of the
second band and equal intensities of the other three glycoforms.
The signal of sGP4-Tm corresponded with the lower band of
GP4-Tm (Figure 2B), confirming that this represents the
unglycosylated GP4-Tm. Mutating the N-glycan sites seemed to
have a deleterious effect on the accumulation of sGP4-Tm, as
shown by the low intensity of its corresponding band. All fusions of
GP4, GP4-Tm and sGP4-Tm with pFc, mFc3, mFc2a and GFP
migrated at their expected theoretical Mw (Table 1), but with
different signal intensities (Figure 2B), pointing toward differences
in antigen accumulation in the seed. For GP4-Tm:mFc2a some
non-reduced homodimers were visible around 100 kDa together
with degraded fragments at 25 kDa (Figure 2B). To a lesser extent,
non-reduced multimers and degradation products could also be
observed for some of the other antigens (Figure 2B).
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Western blot analysis of seed extracts containing the different
GP5 antigens and detected with the a-GP5 mAb II5D (which
recognizes the linear epitope DSSTYQYIYNLT [41]), showed
only for GP5-Tm:pFc a weak signal at 50 kDa (Figure 2C, left
panel). In all samples however, even in the wild-type extract, a
strong background band appeared around 20–25 kDa, possibly
covering other signals. A similar pattern was observed when the a-
GP5 mAbs II5A and VII2H were used to detect the antigens (data
not shown, it should however be noted that the mAbs II5D, II5A
and VII2H recognize the same linear epitope [41]). Western blot
analysis was further performed with an antibody against the
His6-tag, which was also present in the constructs (Figure 1C) and
enabled detection of all GP5 antigens (Figure 2C, right panel). As
expected, GP5 migrates slower than GP5-Tm. The smaller, faint
bands were hypothesized to represent partially or unglycosylated
proteins, since both GP5 and GP5-Tm carry two N-glycosylation
sites, and this was confirmed by deglycosylation analyses (see next
section). GP5:pFc migrates slower than GP5-Tm:pFc, but is only
Figure 1. Schematic representation of the T-DNA bearing the seed-specific expression cassette (A), the PRRSV glycoproteins
selected to be included in a vaccine (B) and the antigen formats derived thereof (C). (A) The T-DNA carrying the neomycin
phosphotransferase II gene which confers resistance to the antibiotic kanamycin and the cassette for high seed-specific expression driven by the b-
phaseolin promoter, the leader sequence of the tobacco mosaic virus and the arcelin-5I terminator. The cassette is further supplemented with
sequences encoding an ER-targeting and retention signal. (B) The full-length PRRSV glycoproteins used in the current study and supplemented with a
His6-tag (purple rod). The jagged line depicts the Tm. The full-length GP3 is placed between brackets as it was never produced as such. Only the GP3
without Tm was expressed, depicted as GP3-Tm in (C). (C) Overview of the manipulations performed on the GPs and the resulting set of antigenic
proteins whose coding sequences were cloned into the seed-specific expression cassette. Abbreviations and symbols used: LB and RB, T-DNA left and
right border, respectively; 39ocs, 39end of the octopine synthase gene; nptII, the neomycin phosphotransferase II gene; Pnos, promoter of the
nopaline synthase gene; Pphas, promoter of the b-phaseolin gene; V, leader sequence of the ‘tobacco mosaic virus’; SS, sequence coding for the
signal peptide of the 2S Arabidopsis seed storage protein; GOI, gene of interest; KDEL, coding sequence of the ER-retention signal; 39Arc, terminator of
the arceline5-I gene; Tm, transmembrane domain, jagged line; His6-tag, immobilized metal affinity chromatography tag, purple rod; pFc, porcine IgG3
Fc, chain of blue ovals; mFc2a, murine IgG2a Fc, chain of orange ovals; mFc3, murine IgG3 Fc, chain of yellow ovals; GFP, green fluorescent protein,
bright green oval.
doi:10.1371/journal.pone.0091386.g001
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very faintly detected, indicating low expression. GP5-Tm:pFc on
the other hand accumulates notably higher than the other GP5
antigens, but also shows a second band migrating at a size smaller
than the theoretical Mw of 49 kDa, which does not correspond
with the partially or unglycosylated proteins, but represents a
cleavage product (see next section).
In conclusion, all antigens, except the GP3-Tm for which no
transformants could be obtained, are present in the seed of the
transgenic A. thaliana and accumulate to different levels. Also, aside
from GP5-Tm:pFc that is partially cleaved, all antigens appear
structurally integer and migrate according to their expected size.
Glycosylation of antigens produced in A. thaliana seed
All antigens were translocated to the ER by an ER-targeting
signal derived from the 2S albumin seed storage protein of A.
thaliana [43] and retained there via a C-terminal KDEL sequence
[44]. If the antigens are indeed retained in the ER, they should
carry N-glycans of the high-mannose type [45]. To verify their
glycosylation status, all antigens (18 in total) were deglycosylated
by treatment with either endoglycosidase H (endoH) or peptide-N-
glycosidase F (PNGaseF), which differ in their substrate specificity.
EndoH acts on high-mannose N-glycans only [46], whereas
PNGaseF processes all N-glycans except core a1,3-fucosylated
structures. In plants, this modification occurs in the late Golgi
apparatus and can be found on hybrid and complex N-glycans
[47]. When the antigen carries ER-typical high-mannose N-
glycans, it will be deglycosylated by both enzymes. However, if the
antigen is present in other compartments of the secretory pathway
and its glycans undergo maturation into hybrid or complex type
glycans, then treatment with endoH and PNGaseF will yield
Figure 2. Characterization of the GP3, GP4 and GP5 antigens. Seed extracts of homozygous lines (unless stated differently) producing the
different antigen formats were analyzed by western blotting under reducing conditions. Sixty mg of TSP was loaded. (A) The GP3 antigens detected
with the a-GP3 mAb VII2D [41]. (B) The GP4 antigens detected with the a-GP4 mAb XVI 11C [42]. For the sGP4-Tm, sGP4-Tm:pFc and the GFP:GP4,
segregating T2 stocks were analyzed and for the GFP:GP4-Tm and GP4-Tm:mFc2a, only 15 mg of TSP was loaded. (C) The GP5 antigens detected with
the a-GP5 mAb II5A [41] (left panel) or an antibody against the His6-tag (right panel). For the GP5-Tm:pFc, a T2 segregating stock was analyzed.
Abbreviations used: WT, wild-type seed extract; kDa, kilodalton.
doi:10.1371/journal.pone.0091386.g002
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differential deglycosylation, except for a1,3-fucosylated glycans
that will not be processed by either of both glycosidases. However,
glycoproteins carrying these structures will be resilient to digestion
and hence, can be monitored as well.
All antigens are susceptible to deglycosylation by endoH and
PNGaseF and no differences can be discerned between treatment
with either glycosidase, indicating that the proteins carry high-
mannose N-glycans (Figure 3A, B and C). As hybrid and/or
complex glycans have been reported on KDEL-tagged recombi-
nant proteins before [25,48], it is possible that minute quantities of
these are present on the antigens as well and that the mobility shift
assay did not reveal these. However, the obtained results clearly
identify high-mannose N-glycans as the predominant glycoforms.
For GFP:GP3-Tm some degradation was observed (Figure 3A).
Figure 3B shows that the banded pattern of both GP4 and GP4-
Tm was reduced to a single band corresponding to the fully
deglycosylated antigen, confirming that it indeed represents
different glycoforms. Figure 3B also shows some non-reduced
multimers and degradation for GFP:GP4-Tm and GP4-
Tm:mFc2a. Similarly, for the GP5 antigens no differential
behavior could be observed when treated with endoH or PNGaseF
(Figure 3C). Deglycosylation of GP5 and GP5-Tm showed that the
faint bands present before treatment correspond to partially and
unglycosylated antigens, since both deglycosylation treatments
resulted in the reduction of this pattern to one single band
(Figure 3C). Given that the pattern of GP5-Tm:pFc (right panel,
Figure 2C and 3C) was not reduced to one single band after
endoH or PNGaseF treatment, the lower band does not
correspond to the unglycosylated protein, but to a cleavage
product (Figure 3C right panel).
To conclude, the antigens were post-translationally modified by
N-glycosylation and glycosidase treatment showed that all antigens
are decorated with ER-typical high-mannose N-glycans, indicating
their correct production in the ER.
Accumulation levels of antigens produced in A. thaliana
seed
ELISAs were performed to determine the accumulation level of
the antigens in the transgenic seed and to assess the effect of fusing
them to stabilizing protein domains (Table S1). The antigen
content was expressed as antigen mass per gram of dry seed and,
after measuring the protein concentration of the seed extracts, as
percentage of TSP. For most antigens, T3 homozygous (Ho) lines
were analyzed. When not available, the T2 segregating (Se) seed
stock was used (Table S1). Therefore, it should be taken into
account that, due to a gene dosage effect [22], it is possible that the
accumulation of the antigens, for which a segregating seed stock
was analyzed, could increase when these lines are propagated to
homozygosity. During the ELISA experiments, no signal could be
obtained for GP5 and GP5:pFc. However, western blotting clearly
showed that they were present in seed extracts (Figure 2C, right
panel), and thus GP5 and GP5:pFc antigen accumulation was
determined by signal quantification after western blot analysis via
the His6-tag (data not shown).
A graphical representation of the accumulation of the antigens
(given as percentage of TSP, Figure 4) shows that there was a large
variation, ranging from 0.005% of TSP for sGP4-Tm to 2.74% of
TSP for GFP:GP3-Tm. Some trends could however be observed.
The full-length antigens GP4 and GP5 did not accumulate well
(0.08% and 0.10% of TSP, respectively) and removing their Tm to
generate GP4-Tm and GP5-Tm did not alter this considerably,
Table 1. Physical parameters of the antigens.
Antigen Amino acids N-glycosylation sites Predicted molecular weight (kDa)
Unglycosylated Fully glycosylated
GP3-Tm 166 6 19.2 31.2
GP3-Tm:pFc 407 7 46.3 60.3
GP3-Tm:mFc2a 392 7 44.6 58.6
GFP:GP3-Tm 410 6 46.6 58.6
GP4 176 4 19.5 27.5
GP4:pFc 417 5 46.7 56.7
GFP:GP4 420 4 46.9 54.9
GP4-Tm 158 4 17.6 25.6
GP4-Tm:pFc 399 5 44.7 54.7
GP4-Tm:mFc3 384 6 42.8 54.8
GP4-Tm:mFc2a 384 5 43.0 53.0
GFP:GP4-Tm 402 4 45.0 53.0
sGP4-Tm 158 0 17.6 17.6
sGP4-Tm:pFc 399 1 44.8 46.8
sGP4-Tm:mFc2a 384 1 43.0 45.0
GP5 179 2 19.9 23.9
GP5:pFc 420 3 47.1 53.1
GP5-Tm 119 2 13.6 17.6
GP5-Tm:pFc 381 3 43.1 49.1
The molecular weight of the fully glycosylated antigens was obtained by taking the weight of the unglycosylated antigens and adding to that the number of potential
N-glycosylation sites multiplied by 2 kDa. Abbreviation used: kDa, kilodalton.
doi:10.1371/journal.pone.0091386.t001
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but fusion to stabilizing protein domains increased accumulation
by several factors, up to 2.36% of TSP for GFP:GP4-Tm. Fusions
between GP3-Tm and the same stabilizing domains showed a
similar increase, resulting in percentages as those measured for the
corresponding GP4-Tm fusions. It is noteworthy that addition of
an IgG Fc to the antigens without Tm can have a beneficial effect
on their accumulation, as described by De Buck et al. [49], but
that this is highly dependent of the Fc added. Whereas the mFc3
did not enhance GP4-Tm accumulation, the pFc, and the mFc2a
even more so, notably did so, boosting accumulation from 0.05%
to 0.67% and 1.59% of TSP, respectively. The full-length antigens
appeared to be less prone to manipulation by addition of
stabilizing domains. In contrast to GP4, where addition of the
pFc and GFP had little impact on accumulation (from 0.08% to
0.14% and 0.15% of TSP, respectively), coupling of the pFc to
GP5 actually reduced accumulation of the resulting GP5:pFc
(from 0.10% to 0.01% of TSP). Removing the four N-glycan
attachment sites of GP4-Tm in sGP4-Tm was also deleterious,
since accumulation was diminished from 0.05% to 0.005% of
TSP. Again, addition of the pFc and mFc2a to sGP4-Tm slightly
increased accumulation. Far outperforming any other format, the
N-terminal GFP fusions, i.e. GFP:GP3-Tm and GFP:GP4-Tm,
accumulated to 2.74% and 2.36% of TSP, respectively.
Purification of antigens produced in A. thaliana seed
Several techniques can be used for purification. Antigens fused
to an IgG Fc are suitable for protein-A affinity chromatography,
Figure 3. Glycan analysis of the GP3, GP4 and GP5 antigens. Seed extracts from homozygous lines (unless stated differently) producing the
different antigen formats were treated with endoH or PNGaseF and analyzed by western blotting under reducing conditions. Thirty mg of TSP was
loaded. (A) Glycan analysis of the GP3 antigens detected with the a-GP3 mAb VII2D [41]. (B) Glycan analysis of the GP4 antigens detected with the a-
GP4 mAb XVI 11c [42]. For the sGP4-Tm, sGP4-Tm:pFc and GFP:GP4, a segregating T2 stock was used. (C) Glycan analysis of the GP5 antigens detected
with an antibody against the His6-tag. For the GP5-Tm:pFc, a segregating T2 stock was analyzed. Abbreviations used: -, no treatment; E, endoH
treatment; P, PNGaseF treatment: WT, non-treated wild-type seed extract; kDa, kilodalton.
doi:10.1371/journal.pone.0091386.g003
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whereas the formats carrying a His6-tag can be purified by
immobilized metal affinity chromatography (IMAC).
A high and low accumulating antigen, respectively GFP:GP4-
Tm and GP4-Tm, were selected to be purified by IMAC. The
IMAC purification of GP4-Tm resulted in fractions enriched with
GP4-Tm as observed by western blot analysis (the banded pattern
corresponds to the different glycoforms of GP4-Tm, Figure 5B),
but GP4-Tm co-eluted with contaminating proteins as shown on
the Coomassie-stained gel (Figure 5A). IMAC was thus efficient in
capturing GP4-Tm, however, since the eluted fractions were only
semi-pure, additional steps are necessary to obtain pure GP4-Tm.
No degradation of the GP4-Tm was visible (data not shown). In
contrast to GP4-Tm, the eluted GFP:GP4-Tm was of high purity
(80–82%, Figure 5C). Western blot analysis (Figure 5D) showed
that some GFP:GP4-Tm was still present in the flow through and
after washing to remove imidazole, the final yield was only 40%.
Nonetheless, successive rounds of loading the flow through onto
the column and subsequent elution could increase the recovery up
to 75% (data not shown). Also, small quantities of degraded
GFP:GP4-Tm were visible both in the crude extract as in the
purified samples (Figure 5D). These experiments suggest that when
IMAC is used to purify proteins from crude A. thaliana seed
extracts, some endogenous proteins co-purify and that the level of
contaminating protein depends on the amount of target protein
present in the extract. When the target protein is abundant, then it
is preferentially retained by the column. Low abundant proteins
on the other hand are co-purified with higher levels of endogenous
proteins. In summary, IMAC is suitable to capture GP4-Tm, but
additional steps are necessary to obtain pure protein. Considering
GFP:GP4-Tm and taking a yield penalty into account, IMAC can
be used to directly purify the antigen.
The GP4-Tm antigens fused to pFc, mFc3 and mFc2a were
selected to be purified by protein-A affinity chromatography
(Figure 6). The strong and specific interaction between protein-A
derived from Staphylococcus aureus and the Fc part of the antigens
should allow for efficient purification [50]. Coomassie and western
blot analysis showed that all three Fcs used had affinity for the
protein-A resin and that both low (GP4-Tm:mFc3 in Figure 6C)
and high accumulating antigens (GP4-Tm:pFc and GP4-
Tm:mFc2a, Figure 6A and B, respectively) could be captured
and purified by single-step protein-A chromatography. The
recovery and purity for GP4-Tm:pFc were 55 and 85%,
respectively, and for GP4-Tm:mFc2a 60 and 88%, respectively
(they were not determined for GP4-Tm:mFc3).
Immunogenicity of antigens produced in A. thaliana
seeds
To study the immunogenicity of the plant-produced antigens,
GFP:GP4-Tm, GP4-Tm:mFc2a and sGP4-Tm:mFc2a, all carry-
ing the GP4-Tm, were selected to vaccinate mice. The GP4-Tm
was chosen as a model antigen as it contains a B-cell epitope that
consistently induces neutralizing antibodies upon infection, and
neutralizing antibodies are considered a good correlate for
protection against PRRSV [14,40]. Mice were injected with
5 mg of purified antigen mixed with an oil-in-water adjuvant
following a prime-boost protocol with three weeks between both
vaccinations. Figure 7A shows that after six weeks high titers of
GP4-Tm-specific antibodies were induced by all three antigens as
measured by ELISA. The sera collected at week six were then
subjected to an immuno peroxidase cell monolayer assay (IPMA)
to check for viral antigen recognition (Figure 7B). Despite the high
antibody titers induced by all antigens, only GP4-Tm:mFc2a
generated antibodies capable of PRRSV recognition in IPMA.
Subsequently these sera were shown to have virus neutralizing
capacity in a seroneutralization test (Figure 7C). All three antigens
thus raised high levels of antigen-specific antibodies in a mouse
model, and those of the GP4-Tm:mFc2a vaccinated group were
also able to neutralize the PRRSV.
Upon completion of the murine vaccination trial, a second
study was initiated to assess the immunogenicity of antigens
carrying the pFc in pigs, the in vivo host of the PRRSV. During this
preliminary trial three piglets were vaccinated with an antigen
cocktail consisting of 100 mg purified GP3-Tm:pFc, 100 mg
purified GP4-Tm:pFc and 100 mg purified GP5-Tm:pFc mixed
with an oil-in-water adjuvant following a prime-boost protocol
with a four-week interval between both vaccinations. High
Figure 4. Antigen accumulation in transgenic seeds as determined by ELISA and given as percentage of TSP. Values are the mean of
three biological repeats, error bars represent the standard deviation. Accumulation of the GP3, GP4 and GP5 antigens is depicted as white, grey and
black bars, respectively. Abbreviation used: TSP, total soluble protein.
doi:10.1371/journal.pone.0091386.g004
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GP3-Tm, GP4-Tm and GP5-Tm-specific antibody titers were
obtained after the booster vaccination from week four onward
(measured by ELISA; Figure 8A, B and C). When sera were tested
via IPMA, high titers were found for one piglet from week five
onward, however, no response could be detected for the other two
piglets (Figure 8D). Sera from all three piglets collected at week
five and six were subjected to a seroneutralization test, but no
response above the threshold could be detected (data not shown).
Figure 5. IMAC purification of selected antigens. One gram of homozygous seed stocks containing 0.14 mg GP4-Tm or 7.37 mg of GFP:GP4-Tm
was extracted and subjected to IMAC. Purification of the GP4-Tm was analyzed by 12% SDS-PAGE and Coomassie Blue staining (A) or western
blotting (B). Purification of the GFP:GP4-Tm was analyzed by SDS-PAGE (15%) and Coomassie Blue staining (C) or western blotting (D). All gels were
run under reducing conditions and an antibody against the His6-tag was used to detect the antigens during western blot analysis. Abbreviations
used: S, sample; F, flow through; W, wash; E, elution; kDa, kilodalton.
doi:10.1371/journal.pone.0091386.g005
Figure 6. Protein-A affinity chromatography of selected antigens. For each antigen, one gram of homozygous seeds (equivalent to 0.15 mg
GP4-Tm:mFc3, 2.06 mg GP4-Tm:pFc and 5.15 mg GP4-Tm:mFc2a) was extracted and subjected to protein-A chromatography. Purification of GP4-
Tm:pFc (A), GP4-Tm:mFc2a (B) and GP4-Tm:mFc3 (C) was analyzed by 12% SDS-PAGE and Coomassie Blue staining (upper panels) or western blotting
(lower panels). All gels were run under reducing conditions and the a-GP4 mAb XVI 11C was used to detect the antigens during western blotting.
Abbreviations used: S, sample; F, flow through; W, wash; E, elution; kDa, kilodalton.
doi:10.1371/journal.pone.0091386.g006
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In summary, all antigens vaccinated in mice and piglets
generated high titers of antigen-specific antibodies after the
booster vaccination and the sera of mice vaccinated with GP4-
Tm:mFc2a also had virus neutralizing capacity. In contrast to this,
no such activity could be detected in any of the sera of the
vaccinated piglets.
Discussion
We designed, cloned and successfully expressed a set of
antigenic proteins derived from the GPs of the PRRSV EU-
prototype LV in the seed of A. thaliana. Analysis of antigen
glycosylation status showed that the antigens were post-transla-
tionally modified by N-glycosylation, and that they carried high-
mannose N-glycans, corresponding to their production in the ER
and possibly, also indicating their retention there. For GP4 this
scenario would mean that its single-span transmembrane domain
[10], predicted to leave the KDEL-tag in the cytosol out of reach
of the KDEL receptor, is not correctly inserted into the ER
membrane or, that GP4 is retained in the ER in a KDEL-
independent manner. In animal cells, GP4 is withheld in the ER
until it associates with GP2 and GP3 to form a heterotrimer after
which the complex is released [39] and a similar mechanism might
function in the seed. For GP5, the exact topology of the Tm,
which is predicted to span the ER membrane anywhere from one
to three times [10], is not known, but the presence of high-
mannose glycans would strengthen the hypothesis that the KDEL-
tag is functional.
On the other hand, we cannot exclude that the antigens have
migrated to other subcellular compartments, since recombinant
proteins with ER-typical glycosylation have been found in non-ER
compartments before in the seed of Arabidopsis. Using the same
expression vector, the anti-HIV monoclonal antibody 2G12 was
found almost exclusively in protein storage vacuoles [25], whereas
a synthetic antibody based on the 2G12 was deposited in newly
formed ER-derived vesicles [26] and another synthetic antibody
even in the periplasmic space [23]. All these recombinant proteins
carried the KDEL sequence and were decorated to some extent
with high-mannose glycans, showing that the mere presence of
these glycans is not sufficient to allocate a protein to the ER.
Figure 7. Characterization of the immunogenicity of selected GP4 antigens in a mouse model. Per antigen, eight mice were vaccinated
twice with 5 mg antigen mixed with an oil-in-water adjuvant. The booster vaccination was administered at week three (both vaccinations are
depicted as black arrows). (A) Antigen-specific IgG titers induced by the GFP:GP4-Tm, GP4-Tm:mFc2a and sGP4-Tm:mFc2a at weeks two, four, and six
after vaccination as measured by ELISA. Per vaccinated group, the individual values for each mouse and the mean (horizontal line) are given. (B) The
titers of the sera collected at week six when tested via IPMA. Per vaccinated group the number of mice with a given titer is indicated. (C) The sera at
week six of the GP4-Tm:mFc2a vaccinated mice were subjected to a seroneutralization assay to determine their virus neutralizing activity. The mean
percentage of virus reduction (n= eight mice) in function of the dilution is given, error bars represent the standard deviation.
doi:10.1371/journal.pone.0091386.g007
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Further localization studies are thus needed to pinpoint the exact
subcellular compartment in which the antigens reside.
Despite the advantages offered by the production of recombi-
nant proteins in plants, such as safety, flexible scalability and
complex protein synthesis, low protein yields have been a major
problem during previous studies concerning PRRSV antigens [31–
36]. Antigen accumulation ranged from 0.011% of TSP for
recombinant GP5 expressed transiently in tobacco leaves [34] to
0.65% of TSP for the N protein produced in soybean seed [36].
To overcome this hurdle, we included in our set of antigenic
proteins a number of antigen formats carrying stable protein
domains, such as GFP or an immunoglobulin Fc fragment, which
are expected to increase antigen accumulation. Indeed, a 6-fold
increase (taking into account the similar molecular weight of GP4-
Tm and the pFc domain) in accumulation of the GP4-Tm
component was observed when comparing the GP4-Tm antigen
(0.05% of TSP) to the GP4-Tm:pFc (0.67% of TSP), rising to over
15-fold for the GP4-Tm:mFc2a (1.59% of TSP) and even more
than 20-fold when comparing to the GFP:GP4-Tm (2.36% of
TSP). Considering the GP5 antigens, both GP5 and GP5-Tm
accumulated to about 0.09% of TSP and this rose to 0.83% of
TSP for GP5-Tm:pFc, corresponding to 2.3 mg/g of seed weight.
These numbers are considerably higher than those obtained for
recombinant GP5 produced in banana (0.037% of leaf TSP [31]),
potato (4.7 mg/g of leaf fresh weight [32]), tobacco (0.011% of
TSP [34]) or for a fusion between GP5 and the B subunit of
Escherichia coli heat-labile enterotoxin produced in tobacco (0.015%
of TSP [33]).
Further, our results are in line with those obtained by Obregon
et al. [51] who fused the HIV-1 p24 antigenic protein to the Fc of
human IgA, resulting in a 13-fold increase in antigen accumula-
tion and those of De Buck et al. [49] who could boost the
accumulation of NanobodiesH (antigen-binding domains of
camelid heavy-chain only antibodies) in the seed of Arabidopsis by
10- to 100-fold up to 16% of TSP after fusion with Fcs of different
origin. As a general tendency we observed that adding stabilizing
domains to the truncated antigens GP3-Tm, GP4-Tm and GP5-
Tm had a positive influence on antigen accumulation and that the
extent of this influence depended on the domain added, with GFP
giving the highest accumulation followed by, in decreasing order,
the mFc2a, pFc and mFc3.
GFP has a long history in the field of cell biology and GFP-
fusion proteins have been made for decades [52]. The main goal of
these fusions has always been to create reporter proteins that could
be followed at the cellular level. However, our data indicate that
GFP can also effectively be used to augment target protein
accumulation and, taken into account its stability and the fact that
several GFP-based purification methods have been published
[53,54], fusion to GFP could represent an alternative strategy to
boost target protein production. However, caution should be taken
in the context of vaccination where GFP might interfere with the
immune response raised against the GFP-tagged antigen.
Manipulation of the full-length antigens GP4 and GP5 by
addition of stable protein domains was much less effective,
indicating that the Tm somehow compromises antigen accumu-
lation. Mutating the N-glycan attachment sites of the GP4-Tm
profoundly disturbed accumulation of the resulting deglycosylated
sGP4-Tm. Both sGP4-Tm, as well all fusions herewith, under-
performed when compared to the corresponding glycosylated
formats. It will be interesting to determine whether this is due to
the change in primary structure after amino acid substitution or
because of the absence of N-glycans, possibly resulting in a
Figure 8. Characterization of the immunogenicity of selected antigens carrying the pFc in a porcine model. Three piglets were
vaccinated twice with an antigen cocktail consisting of purified GP3-Tm:pFc, GP4-Tm:pFc and GP5-Tm:pFc mixed with an oil-in-water adjuvant. The
booster vaccination was administered at week four (both vaccinations are depicted as black arrows). At different time points, the titers of IgG
antibodies specific for GP3-Tm (A), GP4-Tm (B) and GP5-Tm (C) was determined. The collected sera were also tested via IPMA and titers of sera
collected from week zero to six given (D).
doi:10.1371/journal.pone.0091386.g008
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perturbation of interaction with chaperones and the quality
control mechanism in the ER. In summary, we observed that
stable protein domains can be added to the antigens as a strategy
to increase antigen accumulation with GFP being most beneficial,
that the effect of such fusions depends on both the antigen and the
stable domain, and that for each antigen the optimal manipulation
should therefore be identified on a case by case basis.
In addition to boosting accumulation, the Fc domains also allow
for protein-A affinity chromatography. We showed that antigens
carrying the pFc, mFc3 and mFc2a and varying in accumulation
between 0.15 and 5.15 mg per gram dry seed could all be purified
by single-step protein-A affinity chromatography with a recovery
of about 60%. On the other hand, single-step IMAC purification
of antigen formats with a His6-tag was restricted to high abundant
antigens such as GFP:GP4-Tm. It seems that some seed proteins
also show affinity for the resin and compete for binding sites on the
IMAC column. If the antigen is low abundant, then more
endogenous proteins will bind and co-elute, lowering the final
antigen purity and increasing the need for an additional
purification step.
The platform to be chosen for subunit vaccine production
should allow for high production and correct folding and assembly
of the antigens. Regarding the latter, it is doubtful that complex
PRRSV antigens can be produced correctly in bacteria. Indeed,
disease enhancement was observed when recombinant GP5 from
E. coli was vaccinated [55]. PRRSV antigens were also produced
in baculovirus infected insect cells, but only low yields were
achieved [56]. Virus-like particles containing GP5 or GP5 and M
could be isolated from the insect cell culture medium, but no yield
parameter was reported [57,58]. Also when PRRSV antigens were
produced in planta, accumulation was rather low, with a maximum
of 0.65% of TSP when the N protein was produced in soybean
seeds [36]. In contrast to previous studies, we managed to produce
several PRRSV-derived antigens to levels of 1% of TSP and
higher, a level considered to be economically relevant [38], and
extracted these to high purity. Subsequently, the immunogenicity
of the plant-produced antigens was assessed in a murine model.
The GFP:GP4-Tm, GP4-Tm:mFc2a and sGP4-Tm:mFc2a were
vaccinated in mice and although all antigens generated high titers
of antigen-specific antibodies, only those induced by GP4-
Tm:mFc2a were virus neutralizing. Whereas both GFP and
mFc2a served to increase antigen accumulation in the seed, the
latter also seemed to function as an immune enhancing tag,
possibly by targeting the antigen to antigen-presenting cells via
interaction with Fc receptors [59,60]. Deletion of the N-glycans by
amino acid substitution was detrimental for antigen immunoge-
nicity, as the sGP4-Tm:mFc2a did not induce virus neutralizing
antibodies. The ER-associated high-mannose glycans thus seem
beneficial for antigen immunogenicity. Indeed, mannosylation of
antigens has been shown to selectively target antigen presenting
cells, thereby enhancing antigen immunogenicity [61,62]. In short,
GP4-derived antigen is capable of eliciting virus neutralizing
antibodies in a murine model, confirming the immunogenicity of
the plant-produced antigens. Upon completion of the murine trial,
antigen immunogenicity was also preliminary assessed in a porcine
model. Three piglets receiving an antigen cocktail consisting of
purified GP3-Tm:pFc, GP4-Tm:pFc and GP5-Tm:pFc developed
high titers of antigen-specific antibodies, but only the sera of one
piglet recognized the PRRSV in the IPMA and no virus
neutralizing activity could be detected. In this respect it is
interesting to mention the findings of Plana-Dura´n et al. [63] who
observed that pigs having received an inactivated PRRSV vaccine
were protected upon challenge even though their sera were
unresponsive in IPMA before challenge. It has also been shown
that some experimental, inactivated PRRSV vaccines confer
partial protection even without the presence of virus neutralizing
antibodies prior to challenge [64]. Due to a priming effect these
vaccinated piglets generate a faster and stronger neutralizing
antibody response after challenge. Taken these considerations into
account, it becomes clear that the antigens need to be further
examined via a challenge experiment to study their capacity to
prime the antibody response, stimulate a cellular response and
reduce viremia. This will allow a final assessment of the protective
capacity of a plant-produced PRRSV vaccine.
In conclusion, we generated a set of antigenic proteins derived
from the PRRSV, incorporating elements known to be important
in immunity against PRRSV, in A. thaliana seed. The antigens were
correctly produced in the ER, accumulated to levels that are
economically relevant and could be purified by single-step affinity
chromatography. The immunogenicity of the plant-produced
antigens was confirmed in a murine model and preliminary tested
in a porcine model. It is now time to perform a challenge
experiment to assess the protective capacity of the plant-produced




All animal experiments were approved by the Local Ethical
Committee of the Faculty of Veterinary Medicine, Ghent
University.
Cloning and generation of transgenic lines
The original sequences of the GP3, GP4 and GP5 genes were
derived from the complete LV-genome (GenBank accession
number M96262.2) and all the cloned genes described in the
following paragraphs were deposited at GenBank (accession
numbers KF983786 to KF983804).
All sequences coding for the antigens containing GP4, GP5 and
their truncated counterparts GP4-Tm, sGP4-Tm, and GP5-Tm
were cloned in the seed-specific expression cassette of the gateway
compatible pPphasGW destination vector [37] containing the b-
phaesolin promoter, the arcelin-5I terminator and the nptII gene for
kanamycin resistance [22]. The sequences of the antigens were
further complemented at their 59 end with the Kozak motif
(CCACC) plus the coding sequence of the ER-targeting signal
peptide from the Arabidopsis 2S seed storage protein and at their 39
end with the coding sequence of the KDEL ER-retention signal.
The genes of the GP4, GP5 and truncated formats GP3-Tm, GP4-
Tm, sGP4-Tm and GP5-Tm were chemically synthesized flanked
by the gateway recombination sites attB1-B2. Additionally, a
sequence coding for six histidines (His6-tag) was inserted upstream
of the KDEL coding sequence. A BP recombination reaction with
the pDON221 and LR reaction with the pPhasGW allowed
transfer of all genes to the destination vector, except those coding
for the GP3-Tm and fusions thereof. The latter were cloned into a
multisite gateway destination vector using the aforementioned
regulatory elements and complemented with the same sequences
encoding the ER-targeting and retention signal, resulting in an
expression vector bearing the bar gene as resistance marker (all
Gateway reactions were performed according to the Gateway
manual protocol). The codon use of all cloned sequences was
optimized to resemble that displayed by Arabidopsis seed storage
proteins and all genes were sequence verified before transfer to the
destination vectors.
Coupling of stabilizing domains to the GP4, GP5 and truncated
formats GP3-Tm, GP4-Tm, sGP4-Tm and GP5-Tm was done via
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classical cloning of the corresponding coding sequences. The
sequence of the porcine IgG3 Fc (accession no: EU372658; pFc)
was added to that of the antigens using a Gateway compatible
pDON221 vector that contained the gene of a camel-like antibody
(a fusion between the antigen-binding domain of a heavy-chain
camel antibody with an Fc fragment of choice) carrying the
porcine IgG3 Fc [65]. The sequence of the antigen binding
domain was swapped by restriction digest with the enzymes EcoRI
and AvrII and replaced by that of the desired antigen. To this goal
the sequences of the GP4, GP5, and truncated counterparts, were
amplified by polymerase chain reaction (PCR) to include the EcoRI
and AvrII restriction sites (Table S2 and S3). An LR reaction
transferred the resulting genes to the pPhasGW.
A similar strategy was followed to incorporate the sequences of
the murine IgG3 Fc (NCBI accession no X00915; UniProt
accession no P03987; mFc3) and IgG2a Fc (derived from the full-
length murine IgG2a heavy chain; NCBI accession no
AAB59660.1). The sequences of the antigen binding domains of
camel-like antibodies with murine IgG3 Fc and IgG2a Fc were
swapped by restriction digest with EcoRI and SacII and substituted
by those of selected antigens that had been amplified by PCR
(Table S2 and S3). In contrast however to the cloning of the
porcine IgG3 Fc, the sequence coding for the His6-tag was no
longer included in the final product. Subsequently, genes were
transferred to the destination vectors by LR reaction.
Concerning the GFP fusions, the sequence of the enhanced
green fluorescent protein (derived from the pFS7(GW) [66]) was
extended in silico at its 59 end with the Kozak and 2S sequence. At
its 39 end the coding sequences of the his6-tag, the GP4-Tm plus
KDEL and a BamHI restriction site were added. The resulting
GFP:GP4-Tm gene was embedded between the attL1–2 sites and
chemically synthesized. By PCR it was extended to form the
GFP:GP4 gene (Table S2 and S3). The GP4-Tm sequence in the
GFP:GP4-Tm gene was swapped by restriction digest with SacII
and BamHI for an amplicon of the GP3-Tm generating the
GFP:GP3-Tm gene (Tabel S1 and S2). LR reaction transferred all
genes to the destination vectors.
Heat shock delivered all expression vectors to Agrobacterium strain
C58C1RifR containing the pMP90 virulence plasmid [67] and the
resulting strains were used to transform Arabidopsis thaliana (L.)
Heyhn, ecotype Columbia 0, by floral dip [68]. Transformed seeds
containing the T-DNA were identified and lines propagated to
homozygosity as detailed in [68]. In short, T1 seeds obtained after
floral dip were grown on selective Murashige and Skoog medium
for three to four weeks at 21uC on a 16-h light/8 h dark cycle.
Twenty transformants were then transferred to soil and grown
under the same conditions. These were selfed and when seed
setting was complete, transferred to a room at 25uC and low
humidity until completely dry. The dry seeds of each transformant
were harvested to obtain twenty T2 seed stocks. These stocks were
screened for the presence of antigen by western blot analysis as
detailed below and seven stocks with high antigen accumulation
were analyzed for the number of integrated T-DNA loci. As the
T1 transformants are per definition hemizygous, the T-DNA locus
number can be determined by the segregation ratio in the T2
generation. To identify the single locus T-DNA integration lines,
seeds of segregating T2 stocks were sown on selective medium and
the observed ratio of germinated over sensitive seeds was
compared to the expected 3:1 segregation ratio for single locus
lines using a x2-statistical test [68]. For each antigen the T2 stock
with the highest antigen content and the T-DNA integrated at a
single locus in the genome was retained and propagated to
homozygosity.
Protein extraction, protein concentration determination,
SDS-PAGE, Coomassie staining and western blot analysis
To characterize the antigen production in transgenic seed, TSP
was extracted as described elsewhere [68] with minor modifica-
tions: 1 ml of cold extraction buffer (50 mM Phosphate buffer,
pH 7.8, 0.3 M NaCl, 0.1% (w/v) 3-[(3-Cholamidopropyl)di-
methylammonio]-1-propanesulfonate hydrate (CHAPS) supple-
mented with an ethylenediaminetetraacetic acid (EDTA) free,
proteinase inhibitor cocktail (1 tablet per 50 ml; Roche)) was
added to 10 mg of liquid nitrogen (N2) frozen, crushed seeds.
Samples were vortexed for 1 minute and centrifuged at
approximately 20,000 g and 4uC for 30 minutes. 700 ml superna-
tant was removed, snap-frozen in liquid N2 and stored at 220uC.
Total protein concentration was determined by the Lowry method
as described in [68].
Seed extracts containing TSP were separated by reducing
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). To visualize proteins by Coomassie staining, the gels were
submerged in InstantBlueTM (Expedeon) solution for an hour and
then washed three times for 20 minutes with double distilled water
(ddH2O). Stained gels were photographed with the Molecular
ImagerH ChemiDocTM XRS+ Imaging System (Biorad). For
western blot analysis the proteins were transferred electrophoret-
ically from a polyacrylamide gel onto Immobilon-P polyvinylidene
fluoride membrane (Millipore, Billerica, MA). Blots were blocked
in 4% (w/v) skimmed milk and 0.1% (v/v) Tween 20 in
phosphate-buffered saline (PBS). Several commercial secondary
antibodies coupled to horse radish peroxidase (HRP) were used to
develop the western blots. Anti-mouse IgG HRP-linked whole
antibody (from sheep, GE healthcare) was used in combination
with the a-GP4 mAb XVI11C and a-GP5 mAbs II5D, II5A and
VII2H at a dilution of 1:5000 in blocking buffer. The a-GP4 mAb
XVIII5G and a-GP3 mAb VII2D were detected with a-mouse
IgG1 (gamma-chain)-HRP (from rabbit, Sigma Aldrich) diluted
1:5000 in blocking buffer. As an antibody against the His6-tag, a
penta-His HRP conjugate (Qiagen) was used diluted 1:2000 in
blocking buffer. Western blotting was further performed as
described in [68] and the released chemiluminescent signal
measured with the abovementioned imaging system. Quantifica-
tion of signal intensities was performed with the Image Lab 3.0
software (Biorad).
Glycan analysis
Seed extracts containing TSP were treated with peptide N-
glycosidase F (PNGaseF, New England Biolabs) and recombinant
endoglycosidase H (endoH, New England Biolabs) to analyze
antigen glycosylation status. Glycosidase reactions were performed
according to the manufacturer’s protocol. In short, to 9 ml of
extract, 1 ml of 106 denaturing buffer was added and the sample
was incubated at 100uC for 10 minutes. Then, for the PNGaseF
digest, 2 ml G7-buffer, 2 ml 10% NP-40 and 2 ml PNGaseF was
added to the sample whereas for the endoH digest, 2 ml reaction
buffer and 1 ml endoH was added. Sample volume was adjusted to
20 ml with ddH2O, after which the sample was incubated at 37uC
for one hour and analyzed by western blotting.
Antigen purification by IMAC
The GP4-Tm and GFP:GP4-Tm antigens were purified by
IMAC on an A¨kta ExplorerH purification system fitted with a His
TrapH Fast Flow column (1ml, GE healthcare). Seed extracts were
prepared in binding buffer (50 mM phosphate buffer pH 7.4,
0.3 M NaCl, 20 mM imidazole, 0.1% CHAPS supplemented with
an EDTA-free proteinase inhibitor cocktail (1 tablet per 50 ml;
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Roche)) by adding frozen and pulverized seeds to cold buffer at a
fixed w/v of 1 g seeds per 70 ml buffer. The extract was vortexed
and centrifuged for 30 minutes at 4uC and 40,000 g to remove cell
debris. The supernatant was removed, passed through a GF-
prefilter (Sartorius) and a MillexH-HP filter unit (Millipore) and
then flowed over the IMAC column. After washing the column
with binding buffer, antigens were eluted with 0.5 M imidazole (in
binding buffer). To remove the imidazole, the antigens were
washed with PBS on AmiconH Ultra centrifugal filters (Millipore,
3 kDa molecular weight cutoff). Antigen purity was determined by
densitometric analysis of Coomassie-stained polyacrylamide gels
using the aforementioned imaging system and the Image Lab 3.0
software (Biorad). Antigen concentration was derived from the
sample optical density at 280 nm measured by a NanoDropH ND-
1000 spectrophotometer.
Antigen purification by protein-A affinity
chromatography
To purify antigens carrying an Fc chain (mFc3, mFc2a or pFc)
protein-A affinity chromatography was performed as described in
[49] with minor modifications. Seed extracts were prepared in
binding buffer (50 mM phosphate buffer pH 7.4, 0.3 M NaCl,
0.1% CHAPS supplemented with an EDTA-free proteinase
inhibitor cocktail (1 tablet per 50 ml; Roche)) by adding frozen
and pulverized seeds to cold buffer at a fixed w/v of 1 g seeds per
70 ml buffer. The extract was vortexed and centrifuged for
30 minutes at 4uC and 40,000 g to remove cell debris. The
supernatant was removed, passed through a GF-prefilter (Sarto-
rius) and a MillexH-HP filter unit (Millipore) and then flowed over
the protein-A column (MabSelect SuRe 1 ml; GE Healthcare)
fitted onto A¨kta ExplorerH purification system. After washing the
column with binding buffer, antibodies were eluted with 1 M
arginine buffer (pH 2.7) and immediately neutralized with 1 M
TrisHCl (pH 9.0). To remove the arginine, the antigens were
washed with PBS on AmiconH Ultra centrifugal filters (Millipore,
3 kDa molecular weight cutoff). Antibody concentration was
derived from the sample optical density at 280 nm measured by a
NanoDropH ND-1000 spectrophotometer.
Antigen purification by gel filtration
After an initial chromatography step, antigens to be used in
ELISA and in the vaccination trials were further subjected to gel
filtration to remove remaining impurities. To this goal, IMAC or
protein-A elution fractions were passed over a Superdex-200
column (GE Healthcare) fitted onto an A¨kta ExplorerH purifica-
tion system with lipopolysaccharide-free PBS as the mobile phase.
Removal of impurities and/or degradation products was assayed
by Coomassie staining of polyacrylamide gels and whenever
necessary, pure, gel-filtrated antigen was concentrated using
AmiconH Ultra centrifugal filters (Millipore, 3 kDa molecular
weight cutoff). The antigen concentration was derived from the
sample optical density at 280 nm measured by a NanoDropH ND-
1000 spectrophotometer.
ELISA to determine antigen accumulation in the seed
The antigen content of the seed of high accumulating lines was
analyzed by ELISA. Seed extracts were prepared as detailed
above, dilution series were made in duplicate with PBS as coating
buffer, loaded onto Maxisorp 96-well plates (Nunc, Sigma Aldrich)
and coated overnight at 4uC. Wells were washed three times with
270 ml washing buffer (PBS, 0.1% (v/v) Tween-20) and this was
repeated between all subsequent steps. Remaining protein-free
binding sites were blocked with 270 ml blocking buffer (PBS, 1%
(w/v) bovine serum albumin (BSA, Sigma Aldrich), 0.1% (v/v)
Tween-20) for 60 minutes at room temperature. 100 ml primary
antibody solution was added and plates incubated for 60 minutes
at room temperature. Secondary antibody solution was added
(100 ml) and plates again incubated for 60 minutes at room
temperature. Plates were then washed five times with washing
buffer and 100 ml 3, 39, 5, 59-Tetramethylbenzidine Liquid
Substrate (TMB, Sigma Aldrich) was added. After 10 minutes,
color development was terminated by addition of 100 ml 1 M HCl
and plates were read at 450 nm in a VERSAmax tunable
microplate reader. Standard curves were derived from duplicate
two-fold serial dilutions of purified antigen, measured values were
plotted against standard curves and antigen content of the seed
calculated after correcting for antigen molecular weight. For
analysis of the GP3-Tm fusion antigens, the mAb a-GP3 VII2D
was used (diluted 25:1000 in blocking buffer) as primary antibody
together with a-mouse IgG1 (gamma-chain)-HRP (from rabbit,
Sigma Aldrich), diluted 1:5000 in blocking buffer, as the secondary
antibody and protein-A purified GP3-Tm:pFc as standard. The
GP4, GP4-Tm and sGP4-Tm containing antigens were analyzed
with the a-GP4 mAb XVIII5G (diluted 25:1000 in blocking
buffer) as primary antibody, the a-mouse IgG1 (gamma-chain)-
HRP (from rabbit, Sigma Aldrich), diluted 1:5000 in blocking
buffer, as the secondary antibody and protein-A purified GP4-
Tm:pFc as standard. For all antigens carrying GP5 or GP5-Tm, a
murine anti His6-tag (Serotec) primary antibody was used (diluted
1:1000 in blocking buffer), together with an a-mouse IgG HRP-
linked whole antibody (from sheep, GE healthcare) as secondary
antibody (diluted 1:5000) and protein-A purified GP5-Tm:pFc as
standard.
Immunization of mice
Six- to eight-week-old female C57BL/6 mice were obtained
from Janvier (Belgium). Mice were housed under specific
pathogen-free conditions. All animal experiments were approved
by the Local Ethical Committee of Ghent University. Mice were
vaccinated twice with a 3-week interval by subcutaneous injection
with either 5 mg purified GFP:GP4-Tm, GP4-Tm:mFc2a or
sGP4-Tm:mFc2a mixed in a 1:1 ratio with the squalene-based
oil-in-water adjuvant AddaVax (Invivogen). The antigens were
isolated and purified from crude seed extracts by IMAC
(GFP:GP4-Tm) or protein-A affinity chromatography (sGP4-
Tm:mFc2a and GP4-Tm:mFc2a), followed by a gel filtration step
as described before. During the trial, blood samples were collected
at week zero (preimmune), two, four and six post immunization.
Serum samples for IPMA and detection of virus neutralizing
antibodies were incubated 30 minutes at 56uC prior to freezing.
Mice were euthanized after the final bleeding at week six.
Characterization of the antibody response in mice
For detection of the a-GP4 antibodies, ELISA was performed
on serum samples with purified GP4-Tm:pFc as antigen. Maxisorp
96-well plates (Nunc, Sigma Aldrich) were coated overnight at 4uC
with 1 mg antigen per well (in 100 ml PBS). Wells were washed
three times with 270 ml washing buffer (PBS, 0.1% v/v Tween-20)
and this step was repeated between all following steps unless stated
differently. Wells were blocked with 270 ml blocking buffer (PBS,
0.1% Tween-20, 1% BSA) for two hours at room temperature.
100 ml of four-fold serial dilutions (diluted in blocking buffer with
an initial dilution of 1:50) of sera were added and plates incubated
for 90 minutes at room temperature. Subsequently 100 ml of goat
anti-mouse IgG-HRP (Southern Biotech) diluted 1:10.000 in
blocking buffer was added and plates incubated 90 minutes at
room temperature. Wells were washed five times with 270 ml
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blocking buffer and 100 ml TMB (Sigma Aldrich) was added. After
10 minutes color development was terminated by addition of
100 ml 1 M HCl and plates were read at 450 nm in a VERSAmax
tunable microplate reader.
To determine if the antibodies elicited by vaccination were able
to recognize the PRRSV, the collected sera were tested via an
IPMA as described elsewhere [69]. Virus neutralizing antibody
titers were detected by a single-replication virus-neutralization test
as described in [64] with minor modifications. Two-fold serial
dilutions of sera (starting from a 1:10 dilution) were mixed with
equal volumes of porcine alveolar macrophage-grown LV
resulting in a final titer of 105 TCID50/ml. Virus-sera mixtures
were incubated for one hour at 37uC and transferred to a 96-well
plate (50 ml/well) with Marc-145 cells that were cultivated
48 hours prior to use. The inoculum was removed after one hour
and replaced by medium, after which the cells were incubated for
another 11 hours, fixed by drying and stored at 220uC. The cells
were stained for PRRSV infection with mAb 13E2 [41] against the
nucleocapsid protein of PRRSV and peroxidase conjugated goat
a-mouse polyclonal antibodies (Dako), followed by development
with 3-amino-9-ethylcarbazole. The number of infected cells in
each well was counted in three fields at 2006magnification, and
expressed relative (%) to the mean number of infected cells for all
mock conditions within the same experiment.
Immunization of piglets
Three piglets four weeks of age were purchased from a PRRSV-
negative farm, their PRRSV-seronegative status was confirmed by
IPMA [69] upon arrival and animals were housed in isolation
units with HEPA-filtered air. Heat lamps were provided during
the first few weeks and piglets were fed grains sprinkled with milk
powder and had access to water ad libitum. The animal
experiment was approved by the local ethical committee of the
Faculty of Veterinary Medicine, Ghent University. The three
piglets were injected twice in the neck muscles behind the ear
(intramuscular) with an experimental vaccine following a prime –
boost protocol. The vaccine consisted of an antigen cocktail
containing 100 mg purified GP3-Tm:pFc, 100 mg purified GP4-
Tm:pFc and 100 mg purified GP5-Tm:pFc (300 mg antigen in
total) mixed with an oil-in-water adjuvant in a 1:1 ratio (Suvaxyn,
Fort Dodge Animal Health). The antigens were isolated and
purified from crude seed extracts by protein-A affinity chroma-
tography followed by a gel filtration step as described before. The
booster vaccination was administered at week four and blood
samples (5 ml taken from the jugular vein with disposable syringes)
were collected at a weekly basis from week zero (preimmune)
onward. Serum samples for IPMA and detection of virus
neutralizing antibodies were incubated 30 minutes at 56uC prior
to freezing. Piglets were euthanized at the end of the experiment
by slow injection of an overdose (15 ml) of a central nervous
system depressant (Natrium Pentobarbital 20%) in the jugular
vein.
Characterization of the antibody response in piglets
Different ELISA protocols were used to measure the a-GP3, a-
GP4 and a-GP5 antibodies in the piglet sera. To detect the a-GP3
and a-GP4 antibodies, purified GP3-Tm:mFc2a or GP4-
Tm:mFc2a was used as antigen respectively. ELISA was further
performed as described above except that 100 ml of polyclonal a-
porcine IgG-HRP diluted 1:40.000 in blocking buffer was added
to the wells to detect the a-GP3 or a-GP4 antibodies. To measure
a-GP5 antibodies, the wells were coated with a seed extract
containing the GP5-Tm. To this goal one gram of homozygous
GP5-Tm seed stock was extracted with 10 ml of PBS, the extract
diluted 1:100 in PBS and 100 ml containing 0.3 mg GP5-Tm
added to the wells. Plates were incubated overnight at 4uC and
protocol was followed as described for the a-GP3 and a-GP4
antibodies. To determine if the antibodies elicited by vaccination
were able to recognize the PRRSV, the collected sera were tested
via an IPMA as described elsewhere [69]. Virus neutralizing
antibody titers were detected by a single-replication virus-
neutralization test as described above.
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